An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin

Abstract

PurposeThe aim of this study was to investigate the efficacy and tolerability of switching from 0.2 mg tamsulosin to 0.4 mg tamsulosin oral controlled absorption system (OCAS) over a 12-week period in Taiwanese men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).Patients and methodsTaiwanese male patients who were dissatisfied with treatment with 0.2 mg tamsulosin were enrolled in this clinical study and switched to 0.4 mg tamsulosin OCAS. Efficacy was assessed over a 12-week period by an International Prostate Symptom Score (IPSS) questionnaire and analysis of urinary flow by uroflowmetry.ResultsA statistically significant improvement was observed in total IPSS scores from baseline (14.94±7.41, moderate) to 12 weeks (7.36±5.77, mild) in 81 patients who were switched from 0.2 to 0.4 mg tamsulosin OCAS (P<0.001). The IPSS subscores for storage, voiding, nocturia, and quality of life (QOL) were also significantly improved over the 12-week period. Uroflowmetry analysis demonstrated significantly increased maximum flow rate, average flow rate, and mean voided volume from baseline to the end of the 12-week period. The 0.4 mg tamsulosin OCAS dose was well tolerated, with only mild dizziness (five patients) and headache (two patients) as the most frequent adverse events. No clinically significant reduction was observed in blood pressure or vital signs.ConclusionTreatment with 0.4 mg tamsulosin OCAS in Taiwanese men with LUTS associated with BPH who were dissatisfied with 0.2 mg tamsulosin significantly improved IPSS scores, urinary flow, and QOL and was well tolerated, suggesting that this should be the recommended dose offered to Taiwanese male patients.

Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation

“…In this study, we were not able to compare the individuals in the combination group with the placebo control because PE patients who have eagerly waited for effective treatments usually have a higher dropout rate when the therapy is suboptimal, with the dropout rates in some reports even reaching 70.6% (Jern et al, ). Furthermore, the adverse events rate of the 0.4 mg dose of tamsulosin was as high as 11%~14.11%, which may further increase the loss of follow‐up with patients whose primary purpose was to treat premature ejaculation (Kim, Han, Sung, Choo, & Lee, ; Yang, Chen, Hou, Lin, & Tsui, ). Thus, we chose a 0.2 mg dose of tamsulosin and not a 0.4 mg dose as the appropriate dosing schedule in this study.…”

Safety and efficacy of tamsulosin 0.4 mg as an initial dose in 1,219 Korean patients with moderate to severe lower urinary tract symptoms: data from a phase IV study

“… 8 Recent studies have reported that increasing the dose of tamsulosin to 0.4 mg is effective and safe in Asian men with LUTS who do not respond to an initial dose of 0.2 mg tamsulosin. 9 , 10 , 11 , 12 However, it is still unclear whether tamsulosin 0.4 mg as the initial dose is effective and safe in Asian men with LUTS. To the best of our knowledge, only one randomized clinical, double-blind, phase 3 trial has been reported thus far.…”

Effect of Transcutaneous Acupoint Electrical Stimulation on Urinary Retention and Urinary ATP in Elderly Patients After Laparoscopic Cholecystectomy: A Prospective, Randomized, Controlled Clinical Trial

“… 5 Aging is a physiological process associated with dysfunction of the autonomic nervous system. 6 , 7 The physiological response to anesthesia may be unpredictable and paradoxical if the autonomic nervous system is dysfunctional. ATP, the principal messenger released from urothelial cells, is a co-transmitter together with noradrenaline in sympathetic nerves and acetylcholine in parasympathetic nerves and considered a potential therapeutic target for functional bladder functional disorders.…”